Artesunate 50 Mg
$34 – $89
Generic Drugs | Artesunate |
Manufacturer | Troikaa Pharmaceuticals Ltd |
Pack Size | Price | Price Per Unit | Quantity | Add To Cart |
---|---|---|---|---|
96 Tablet/s | $89 | $0.92 | ||
64 Tablet/s | $64 | $1.00 | ||
32 Tablet/s | $34 | $1.06 |
Artesunate 50 Mg
Artesunate 50 Mg is a water-soluble hemisuccinate derivative of artemisinin. It is unstable in neutral solution and the injectable formulation must be prepared immediately before use in 5% (w/v) sodium bicarbonate solution to produce the salt sodium Artesunate 50 Mg.
After parenteral administration, it is rapidly hydrolysed to the active metabolite dihydroartemisinin. The oral formulation is probably hydrolysed completely before entering the systemic circulation.
Artesunate 50 Mg has been reported to clear fever in patients with severe falciparum malaria 16-25 hours after parenteral administration.
Drug = Artesunate
Strength = 50 Mg
Manufacturer = Troikaa Pharma
How ToTake
Take Artesunate 50 Mg in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Artesunate 50 Mg Tablet may be taken with or without food, but it is better to take it at a fixed time.
Dosage
Artesunate 50 Mg
Side Effects
Urticaria
Rash
Hemoglobinuria
Seizures
Neuropsychiatric reactions
Reversible neurologic changes
Warning
Contraindications: Hypersensitivity to artemisinins
Cautions: Rare, delayed post-artemisinin hemolytic anemia reported; monitor for up to 4 wk after treatment; patients with higher parasitemias may be more prone to hemolytic anemia
Uses
Orally: treatment of uncomplicated falciparum malaria in areas where there is evidence of chloroquine, pyrimethamine/sulfadoxine, mefloquine and quinine resistance. It should always be administered together with mefloquine in full therapeutic dose.
Parenterally: treatment of severe falciparum malaria in areas where there is evidence of quinine resistance. Radical cure is then effected with a full course of an effective oral antimalarial.
Reviews
There are no reviews yet.